Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases.

@article{Nozawa1997SolubleF,
  title={Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases.},
  author={Kazuhisa Nozawa and Nobuhiko Kayagaki and Yoshiaki Tokano and Hideo Yagita and K. S. Okumura and Hiromi Hasimoto},
  journal={Arthritis and rheumatism},
  year={1997},
  volume={40 6},
  pages={
          1126-9
        }
}
OBJECTIVE To assess levels of soluble Fas (sFas) and soluble Fas ligand (sFas-L) in sera from patients with various rheumatic diseases: systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), mixed connective tissue disease (MCTD), and Sjogren's syndrome (SS). METHODS Levels of sFas and sFas-L were determined by a sandwich enzyme-linked immunosorbent assay. RESULTS In SLE, PM/DM, MCTD, and SS, sFas levels were… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 47 CITATIONS

Similar Papers

Loading similar papers…